OSIVAX
  • COMPANY
    • ABOUT US
    • EXECUTIVE COMMITTEE
    • SCIENTIFIC ADVISORY BOARD
    • CLINICAL ADVISORY BOARD
    • BOARD OF DIRECTORS
    • PARTNERS
  • SCIENCE
  • PIPELINE
    • OVERVIEW
    • INFLUENZA - OVX836
    • CORONAVIRUS
  • NEWS
    • PRESS RELEASES
    • MEDIA COVERAGE
    • PUBLICATIONS
    • EVENTS
  • CONTACT
    • CAREERS >
      • Office Manager Contrat à temps partiel, basé à Liège (Angleur)
    • LEGAL MENTIONS

NEWS

PRESS RELEASES

MEDIA COVERAGE
publications
EVENTS

2020

September 2020
Osivax annouces Last Subject Last Visit  completed in Phase 2a Clinical trial of OVX836 Universal Influenza Vaccine Candidate
​July 2020
Osivax Receives Over EUR 30M in Public Funding to Support Development of Universal Coronavirus & Influenza Vaccines
April 2020
OSIVAX Announces Completion of Enrolment in its Phase 2a Clinical Trial of OVX836 Universal Influenza Vaccine Candidate
January 2020
Osivax Announces First Volunteers Enrolled in Phase 2a clinical trial of OVX836 Universal Influenza Vaccine Candidate 

2019

December 2019
Osivax Enters Agreement with U.S. National Institutes of Health to Test Universal Flu Vaccine Candidate 

​October 2019
Osivax Extends Executive Team to strengthen Corporate Expansion and Accelerate the Development of Universal Flu Vaccine Candidate

September 2019
Osivax Announces Last Participant Last Visit in its Phase 1 Clinical Trial of OVX836 Universal Influenza Vaccine Candidate

​July 2019
Osivax Secures EUR 8 Million of Financing through a Series A Round

​January 2019
Osivax appoints Dr. Paul Willems as Chief Medical Officer​

2018


June 2018
Approval of Osivax’ First in Human Clinical Trial for its Universal Influenza Vaccine Candidate​
​
April 2018
Osivax strengthens its collaboration with the German Cancer Research Center (DKFZ)

February 2018
Osivax appoints Prof. Jeffrey Almond, pre-eminent Vaccinologist, as Chairman of its Scientific Advisory Board

January 2018
​Osivax appoints Dr. Delphine Guyon-Gellin as Chief Business Development Officer

2017

​June 2017
Creation of OSIVAX, a spin-off taking over IMAXIO's R&D activity, with a €2.7 million seed funding round

Proudly powered by Weebly
  • COMPANY
    • ABOUT US
    • EXECUTIVE COMMITTEE
    • SCIENTIFIC ADVISORY BOARD
    • CLINICAL ADVISORY BOARD
    • BOARD OF DIRECTORS
    • PARTNERS
  • SCIENCE
  • PIPELINE
    • OVERVIEW
    • INFLUENZA - OVX836
    • CORONAVIRUS
  • NEWS
    • PRESS RELEASES
    • MEDIA COVERAGE
    • PUBLICATIONS
    • EVENTS
  • CONTACT
    • CAREERS >
      • Office Manager Contrat à temps partiel, basé à Liège (Angleur)
    • LEGAL MENTIONS